Oxford Immunotec (OXFD) Reports Q4 EPS of $0.33, Slight Miss on Revenues

Note: EPS may not be comparable

Oxford Immunotec (NASDAQ: OXFD) reported Q4 EPS of $0.33, versus ($0.18) reported last year. Revenue for the quarter came in at $25 million versus the consensus estimate of $25.65 million.

• Net income for the fourth quarter of 2017 was $8.8 million, or $0.33 per share on a diluted basis, compared to a net loss $4.9 million, or $0.22 per share in the fourth quarter of 2016.
• Revenue for the fourth quarter of 2017 was $25.0 million, representing 6% growth over the fourth quarter 2016 revenue of $23.7 million.

For earnings history and earnings-related data on Oxford Immunotec (OXFD) click here.

You May Also Be Interested In

• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• Cue Biopharma, Inc. (CUE) Misses Q2 EPS by 2054c
• Jasper Therapeutics (JSPR) Tops Q2 EPS by 18c